%0 Journal Article
%T JAK2 inhibitors and transplant in myeloproliferative neoplasms
%A A.M. Vannucchi
%J Drugs and Cell Therapies in Hematology
%D 2013
%I PAGEPress Publications
%R 10.4081/dcth.2013.1s.45
%X Among the chronic myeloproliferative neoplasms (MPN), primary myelofibrosis (PMF) has the most severe course with a median survival of less than 6 years, although some patients survive longer than 10 years and an improved survival has been demonstrated in recent years. Causes of death among 1054 PMF patients reported by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) were represented by leukemia in 31%, accelerated phase without leukemia transformation in 19%, thrombosis in 14%, bleeding in 5%, infections in 10%, portal hypertension in 4%, second neoplasia in 4%, and other causes in 10%...
%K JAK2
%K transplant
%K myeloproliferative neoplasms.
%U http://www.dcth.org/dcth/article/view/35